Evidence map›Paper›PMID 24789375›Full record

Trial reportJAMA ophthalmology2014

Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial.

Michael X Repka, Raymond T Kraker, Jonathan M Holmes, Allison I Summers, Stephen R Glaser, Carmen N Barnhardt, David R Tien, Pediatric Eye Disease Investigator Group

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000170 (Amblyopia Treatment Study), which is not on this map. Cited by 57 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 7 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000170 phase3completednot on this map

Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

TypeinterventionalSponsorJaeb Center for Health ResearchRan1999 to 2013Enrolled419ConditionsAmblyopiaArmsAtropine, Eye Patch
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 7 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Occlusion for stimulus deprivation amblyopia.The Cochrane database of systematic reviews · 2020
    Pooled it
  5. Conventional occlusion versus pharmacologic penalization for amblyopia.The Cochrane database of systematic reviews · 2019
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. A pilot randomized clinical trial of intermittent occlusion therapy liquid crystal glasses versus traditional patching for treatment of moderate unilateral amblyopia.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2016
    Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Prospective observational study of three real-world amblyopia treatments in children: clinical outcomes and predictive factors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Observational
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Michael X RepkaWilmer Ophthalmological Institute, The John Hopkins University, Baltimore, Maryland.
Raymond T KrakerPediatric Eye Disease Investigator Group Coordinating Center, Jaeb Center for Health Research, Tampa, Florida.
Jonathan M HolmesDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
Allison I SummersCasey Eye Institute, Portland, Oregon.
Stephen R Glasercurrently in private practice, Rockville, Maryland.
Carmen N BarnhardtSouthern California College of Optometry, Fullerton.
David R TienPediatric Ophthalmology and Strabismus Associates, Providence, Rhode Island.
Pediatric Eye Disease Investigator Group
Jaeb Center for Health Research · USMarshall B. Ketchum University · USMayo Clinic · USProvidence College · US

Funding

Pediatric Eye Disease Investigator Group Coordinating CenterU10EY011751 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI KRAKER, RAYMOND · 1997 to 2018
$75.2M
Pediatric Eye Disease Investigator Group NetworkUG1EY011751 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI Raymond Kraker, Stacy Pineles · 2019 to 2026
$53.7M
Pediatric Eye Disease Investigator Group: Chair's OfficeU10EY018810 · NEI · MAYO CLINIC ROCHESTER · PI HOLMES, JONATHAN M · 2009 to 2013
$3.5M
PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICEU10EY023198 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI WALLACE, DAVID K · 2014 to 2018
$1.4M
NEI NIH HHS EY011751NEI NIH HHS EY018810NEI NIH HHS U10 EY011751NEI NIH HHS U10 EY018810NEI NIH HHS U10 EY023198NEI NIH HHS UG1 EY011751
6 · The paper itself

Abstract

importanceInitial treatment for amblyopia of the fellow eye with patching and atropine sulfate eyedrops improves visual acuity. Long-term data on the durability of treatment benefit are needed.

objectiveTo report visual acuity at 15 years of age among patients who were younger than 7 years when enrolled in a treatment trial for moderate amblyopia. DESIGN, SETTING, AND

participantsIn a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40 to 20/100) were randomly assigned to patching (minimum of 6 h/d) or atropine sulfate eyedrops, 1% (1 drop daily), for 6 months. Treatment after 6 months was at the discretion of the investigator. Two years after enrollment, an unselected subgroup of 188 children were enrolled into long-term follow-up.

interventionInitial treatment with patching or atropine with subsequent treatment at investigator discretion. MAIN OUTCOMES AND MEASURES: Visual acuity at 15 years of age with the electronic Early Treatment Diabetic Retinopathy Study test in amblyopic and fellow eyes.

resultsMean visual acuity in the amblyopic eye measured in 147 participants at 15 years of age was 0.14 logMAR (approximately 20/25); 59.9% of amblyopic eyes had visual acuity of 20/25 or better and 33.3%, 20/20 or better. Mean interocular acuity difference (IOD) at 15 years of age was 0.21 logMAR (2.1 lines); 48.3% had an IOD of 2 or more lines and 71.4%, 1 or more lines. Treatment (other than spectacles) was prescribed for 9 participants (6.1%) aged 10 to 15 years. Mean IOD was similar at examinations at 10 and 15 years of age (2.0 and 2.1 logMAR lines, respectively; P = .39). Better visual acuity at the 15-year examination was achieved in those who were younger than 5 years at the time of entry into the randomized clinical trial (mean logMAR, 0.09) compared with those aged 5 to 6 years (mean logMAR, 0.18; P < .001). When we compared subgroups based on original treatment with atropine or patching, no significant differences were observed in visual acuity of amblyopic and fellow eyes at 15 years of age (P = .44 and P = .43, respectively). CONCLUSIONS AND RELEVANCE: At 15 years of age, most children treated for moderate amblyopia when younger than 7 years have good visual acuity, although mild residual amblyopia is common. The outcome is similar regardless of initial treatment with atropine or patching. The results indicate that improvement occurring with amblyopia treatment is maintained until at least 15 years of age.

trial registrationclinicaltrials.gov Identifier: NCT00000170.

Indexed as

BandagesSensory DeprivationAdolescentAmblyopiaAtropineChildChild, PreschoolFollow-Up StudiesHumansMydriaticsOphthalmic SolutionsPatient ComplianceTreatment OutcomeVision, BinocularVisual AcuityAtropineMydriaticsOphthalmic Solutions

Identifiers

PMID24789375
PMCPMC4206086
OpenAlexW2172131290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.